IMI 2 Open Info Day 2014

Start Date 30/09/2014

IMI held its IMI 2 Open Info Day in Brussels on Tuesday 30 September 2014. The event was well-attended, with more than 290 people participating either in person or remotely via the webcast.  On top of a review of the new IMI 2 rules and Call procedures, IMI's founding partners presented their perspectives on IMI 2.  In the afternoon, there were two topic-related workshops on the IMI 2 Call 1 topics, as well as plenty of networking opportunities throughout the day. During the workshops, participants were invited to make an 'elevator pitch' or short presentation to the other participants about their organisation. The final session gave a preview of what's coming later this year in IMI's second IMI 2 Call, giving participants the chance to ask three of the topic writers directly about the new indicative topics.

The whole day's events were recorded and the videos of each session will be viewable on IMI's YouTube channel.


Industry perspective on IMI 2
Magda Chlebus, Director, Science Policy, EFPIA

Commission perspective on IMI 2
Ruxandra Draghia-Akli, Director, Directorate Health, DG Research and Innovation, European Commission

Overview of rules and procedures
Magali Poinot, Legal Manager, IMI
Hugh Laverty, Senior Scientific Project Manager, IMI

Workshop A - Translational approaches to disease modifying therapy of type 1 diabetes mellitus
Anke Schulte, Research & Translational Medicine, Sanofi-Aventis

Workshop B - Discovery and validation of novel endpoints in retinal diseases
Oliver Zeitz, Global Clinical Development Ophthalmology, Bayer

Introduction to IMI 2 Call 2 indicative topics
Elisabetta Vaudano, Scienicstific Pillar Coordinator, IMI

RADAR Remote assessment of disease and relapse
Theo Meert, Senior Director External Innovations NS, Janssen Research & Development, J&J

Assessing risk and progression of pre-diabetes and type 2 diabetes to enable disease modification
Bernd Stowasser, Head of European Public Partnerships, Sanofi-Aventis

Towards a quantitative biological approach for neuropsychiatry
Hugh Marston, ‎Head of In Vivo Pharmacology, Eli Lilly

Download the agenda

IMI 2 - Call 1 was launched in July. The full topic texts and details of how to apply can be found here

IMI 2 - Call 2 topics outlines are now also available here